<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2106222242
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEXIUM 40MG VIAL POWDER FOR IV. INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        185.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASTRAZENECA PHARMACEUTICAL LTD" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASTRAZENECA PHARMACEUTICAL LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nexium contains a medicine called esomeprazole. This belongs to a group of medicines called &#39;proton pump inhibitors&#39;. They work by reducing the amount of acid that your stomach produces.</p><p>Nexium is used to treat the following conditions:</p><p>&nbsp;</p><p>Adults</p><p>&bull; &#39;Gastroesophageal reflux disease&#39; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>&bull; Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &#39;Helicobacter pylori&#39;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>&nbsp;</p><p>&bull; Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Nexium can also be used to stop stomach ulcers from forming if you are taking NSAIDs.</p><p>&bull; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p>&bull; Prolonged treatment after prevention of rebleeding of ulcers with intravenous Nexium.</p><p>&nbsp;</p><p>Adolescents aged 12 years and above</p><p>&bull; &#39;Gastroesophageal reflux disease&#39; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>&bull; Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &#39;Helicobacter pylori&#39;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp; Do not take Nexium if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic (hypersensitive) to esomeprazole or any of the other ingredients of this medicine (listed in Section 6: Further information).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lanzoprazole, rabeprazole, omeprazole).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are taking a medicine containing nelfinavir (used to treat HIV).</p><p>Do not take Nexium if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Nexium.</p><p>&nbsp;</p><p>Children under the age of 12 years: Information on dosing for children aged 1 to 11 years is provided in Nexium sachet product information (ask your doctor or pharmacist if you require further information).</p><p>&nbsp;</p><p>Take special care with Nexium</p><p>Check with your doctor or pharmacist before taking Nexium if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe liver problems.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have severe kidney problems.</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a skin reaction after treatment with a medicine similar to Nexium that reduces stomach acid.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are due to have a specific blood test (Chromogranin A).</p><p>&nbsp;</p><p>&nbsp;</p><p>Nexium may hide the symptoms of other diseases. Therefore, if any of the following</p><p>&nbsp;</p><p>happen to you before you start taking Nexium or while you are taking it, talk to your doctor straight away:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You get stomach pain or indigestion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You begin to vomit food or blood.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You pass black stools (blood-stained faeces).</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have been prescribed Nexium &quot;on demand&quot; you should contact your doctor if your symptoms continue or change in character.</p><p>&nbsp;</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Nexium. Remember to also mention any other ill-effects like pain in your joints.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Taking a proton pump inhibitor like Nexium, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your</p><p>doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&nbsp;</p><p>Using other medicines</p><p>Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines. This includes medicines that you buy without a prescription. This is because Nexium can affect the way some medicines work and some medicines can have an effect on Nexium.</p><p>Do not take Nexium Tablets if you are taking a medicine containing nelfinavir (used to treat HIV).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atazanavir (used to treat HIV).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erlotinib (used to treat cancer)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Citalopram, imipramine or clomipramine (used to treat depression).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to</p><p>&nbsp;</p><p>monitor you when you start or stop taking Nexium.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop taking Nexium.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cilostazol (used to treat intermittent claudication - a pain in your legs when you walk which is caused by an insufficient blood supply).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride (used for indigestion and heartburn).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin (used for heart problems).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) - if you are taking a high dose of methotrexate, your doctor may temporarily stop your Nexium treatment.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus (organ transplantation)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clopidogrel (used to prevent blood clots).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used for treatment of tuberculosis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&#39;s wort (Hypericum perforatum) (used to treat depression).</p><p>&nbsp;</p><p>&nbsp;</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as Nexium to treat ulcers caused by Helicobacter pylori infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>Before taking Nexium, tell your doctor if you are pregnant or trying to get pregnant . Ask your doctor or pharmacist for advice before taking any medicine. Your doctor will decide whether you can take Nexium during this time.</p><p>It is not known if Nexium passes into breast milk. Therefore, you should not take Nexium if you are breastfeeding.</p><p>&nbsp;</p><p>Taking Nexium with food and drink</p><p>You can take your tablets with food or on an empty stomach.</p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines</p><p>Nexium is not likely to affect you being able to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines</p><p>&nbsp;</p><p>Important information about some of the ingredients of Nexium</p><p>Nexium gastro-resistant tablets contain sucrose, which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Nexium exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nexium gastro-resistant tablets are not recommended for children less than 12 years old.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has told you to take this medicine as and when you need it, tell your doctor if your symptoms change.</p><p>&nbsp;</p><p>Taking this medicine</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablets at any time of the day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablets with food or on an empty stomach.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow your tablets whole with a drink of water. Do not chew or crush the tablets. This is because the tablets contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p>&nbsp;</p><p>What to do if you have trouble swallowing the tablets</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have trouble swallowing the tablets:</p><p>-&nbsp;&nbsp; Put them into a glass of still (non-fizzy) water. Do not use any other liquids.</p><p>-&nbsp;&nbsp; Stir until the tablets break up (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it.</p><p>-&nbsp;&nbsp; To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot swallow at all, the tablet can be mixed with some water and put into a</p><p>syringe. It can then be given to you through a tube directly into your stomach</p><p>&nbsp;</p><p>(&#39;gastric tube&#39;).</p><p>&nbsp;</p><p>&nbsp;</p><p>How much to take</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you how many tablets to take and how long to take them for. This will depend on your condition, how old you are and how well your liver works.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual doses are given below.</p><p>&nbsp;</p><p>&nbsp;</p><p>Use in adults aged 18 and above</p><p>&nbsp;</p><p>To treat heartburn caused by gastroesophageal reflux disease (GERD):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is one Nexium 40 mg gastro-resistant tablet once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose once the gullet has healed is one Nexium 20 mg gastro- resistant tablet once a day</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your gullet has not been damaged, the recommended dose is one Nexium 20 mg gastro-resistant tablet each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one Nexium 20 mg gastro-resistant tablet each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one Nexium 20 mg gastro-resistant tablet twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one Nexium 20 mg gastro-resistant tablet once a day for 4 to 8 weeks.</p><p>&nbsp;</p><p>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one Nexium 20 mg gastro-resistant tablet once a day.</p><p>&nbsp;</p><p>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is Nexium 40 mg twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.</p><p>&nbsp;</p><p>Prolonged treatment after prevention of re-bleeding of ulcers with intravenous Nexium:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one Nexium 40 mg tablet once a day for 4 weeks.</p><p>&nbsp;</p><p>&nbsp;</p><p>Use in adolescents aged 12 or above</p><p>To treat heartburn caused by gastroesophageal reflux disease (GERD):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is one Nexium 40 mg gastro-resistant tablet once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose once the gullet has healed is one Nexium 20 mg gastro- resistant tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your gullet has not been damaged, the recommended dose is one Nexium 20 mg gastro-resistant tablet each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one Nexium 20 mg gastro-resistant tablet twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p>Elderly:</p><p>Dose adjustment is not required in the elderly.</p><p>&nbsp;</p><p>If you take more Nexium than you should:</p><p>If you take more Nexium than prescribed by your doctor, talk to your doctor or pharmacist straight away</p><p>&nbsp;</p><p>If you forget to take Nexium</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Nexium can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you notice any of the following serious side effects, stop taking Nexium and contact a doctor immediately:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &#39;Stevens-</p><p>&nbsp;</p><p>Johnson syndrome&#39; or &#39;toxic epidermal necrolysis&#39;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p>&nbsp;</p><p>&nbsp;</p><p>These effects are rare, affecting less than 1 in 1,000 people. Other side effects include:</p><p>Common (affects less than 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp; Headache.</p><p>&bull;&nbsp;&nbsp;&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) or being sick (vomiting).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Benign polyps in the stomach</p><p>&nbsp;</p><p>Uncommon (affects less than 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp; Swelling of the feet and ankles.</p><p>&bull;&nbsp;&nbsp;&nbsp; Disturbed sleep (insomnia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Dizziness, tingling feelings such as &quot;pins and needles&quot;, feeling sleepy.</p><p>&bull;&nbsp;&nbsp;&nbsp; Spinning feeling (vertigo).</p><p>&bull;&nbsp;&nbsp;&nbsp; Dry mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in blood tests that check how the liver is working.</p><p>&bull;&nbsp;&nbsp;&nbsp; Skin rash, lumpy rash (hives) and itchy skin.</p><p>&bull;&nbsp;&nbsp;&nbsp; Fracture of the hip, wrist or spine (if Nexium is used in high doses and over long duration).</p><p>&nbsp;</p><p>Rare (affects less than 1 in 1,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely</p><p>&bull;&nbsp;&nbsp;&nbsp; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.</p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling agitated, confused or depressed.</p><p>&bull;&nbsp;&nbsp;&nbsp; Taste changes.</p><p>&bull;&nbsp;&nbsp;&nbsp; Eyesight problems such as blurred vision.</p><p>&bull;&nbsp;&nbsp;&nbsp; Suddenly feeling wheezy or short of breath (bronchospasm).</p><p>&bull;&nbsp;&nbsp;&nbsp; An inflammation of the inside of the mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; An infection called &quot;thrush&quot; which can affect the gut and is caused by a fungus.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>&bull;&nbsp;&nbsp;&nbsp; Hair loss (alopecia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Skin rash on exposure to sunshine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Generally feeling unwell and lacking energy.</p><p>&bull;&nbsp;&nbsp;&nbsp; Increased sweating.</p><p>&nbsp;</p><p>Very rare (affects less than 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in blood count including agranulocytosis (lack of white blood cells)</p><p>&bull;&nbsp;&nbsp;&nbsp; Aggression.</p><p>&bull;&nbsp;&nbsp;&nbsp; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>&bull;&nbsp;&nbsp;&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)</p><p>&bull;&nbsp;&nbsp;&nbsp; Muscle weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe kidney problems.</p><p>&bull;&nbsp;&nbsp;&nbsp; Enlarged breasts in men.</p><p>&nbsp;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp; If you are on Nexium for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&bull;&nbsp;&nbsp;&nbsp; Inflammation in the gut (leading to diarrhoea)</p><p>&bull;&nbsp;&nbsp;&nbsp; Rash, possibly with pain in the joints.</p><p>&nbsp;</p><p>Nexium may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important</p><p>&nbsp;</p><p>for you to give information about your medication at this time.</p><p>Do not be concerned by this list of possible side effects. You may not get any of them. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine in the original container (blister) in order to protect from moisture.<br /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-US style='font-size:1.0pt;mso-bidi-font-size:12.0pt;font-family:"Arial Unicode MS",sans-serif'><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take your tablets after the expiry date (EXP) shown on the carton or blister foil. The expiry date refers to the last day of that month.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is esomeprazole. Nexium gastro-resistant tablets come in two strengths containing 20 mg or 40 mg of esomeprazole (as magnesium trihydrate).</p><p>The other ingredients are glycerol monostearate 40-55, hyprolose, hypromellose, iron oxide (reddish-brown, yellow) (E172, 20 mg tablet only), magnesium stearate, methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent, microcrystalline cellulose, synthetic paraffin, macrogol, polysorbate 80, crospovidone, sodium stearyl fumarate, sugar spheres (sucrose and maize starch), talc, titanium dioxide (E171), triethyl citrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Nexium 20 mg gastro-resistant tablets are light pink with an on the other side.
 



A
EH on one side and 20 mg
 

•	Nexium 40 mg gastro-resistant tablets are pink with an the other side.
 

A
EI on one side and 40 mg on
 
•	Your tablets will come in a blister pack in cartons containing 20 mg, 40 mg: Blister packs in carton of 14 and 28 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AstraZeneca UK Luton,</p><p>United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2017 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نكسيوم على دواء يسمى إيزومبرازول. ينتمي هذا الدواء إلى مجموعة من الأدوية يُطلق عليها الأدوية &quot;مثبطات ضخ البروتون&quot;. وهي تعمل على تقليل كمية الحمض الذي تفرزه المعدة.</p><p dir="RTL">يستخدم نكسيوم كعلاج قصير الأمد لحالات محددة إذا كنت لا تستطيع تناول علاج عن طريق الفم. ويُستخدم في علاج الحالات التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>البالغون </strong></p><p dir="RTL">&bull; &quot;مرض الارتجاع المعدي المريئي&quot; (GERD). حيث يتسلل حمض من المعدة إلى المريء (الأنبوب الواصل بين الحلق والمعدة) وهو ما يسبب شعورًا بالألم، والالتهاب، والحرقة.</p><p dir="RTL">&bull; قرحات المعدة الناتجة عن فئة من الأدوية تُسمى الأدوية المضادة للالتهاب غير الاستيرويدية (NSAID). يمكن استخدام نكسيوم كذلك لمنع قرح المعدة من التشكل إذا كنت تتناول أدوية مضادة للالتهاب غير ستيرويدية (NSAID).</p><p dir="RTL">&bull; الوقاية من تكرار النزف بعد الخضوع لتنظير لعلاج النزف المعوي الحاد أو قرحات الاثنى عشر.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون الذين تتراوح أعمارهم م بين عام واحد إلى 18 عامًا </strong></p><p dir="RTL">&bull; &quot;مرض الارتجاع المعدي المريئي&quot; (GERD). حيث يتسلل حمض من المعدة إلى المريء (الأنبوب الواصل بين الحلق والمعدة) وهو ما يسبب شعورًا بالألم، والالتهاب، والحرقة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار نكسيوم:</strong></p><p>&nbsp;</p><p dir="RTL">&bull; إذا كانت لديك حساسية تجاه إيزومبرازول أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull; إذا كانت لديك حساسية تجاه أدوية أخرى مثبطة لضخ البروتون (مثل بانتوبرازول ولانسوبرازول ورابيبرازول وأومبرازول).</p><p dir="RTL">&bull; إذا كنت تتناول دواءً يحتوي على نيلفينافير (المستخدم في علاج عدوى فيروس نقص المناعة البشري (فيروس الإيدز)).</p><p>&nbsp;</p><p dir="RTL">لا تتناول نكسيوم في حال ما انطبق عليك أيٌّ مما سبق. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الممرضة قبل أن تُعطى هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>التزم الحذر الشديد عند تناول عقار نكسيوم:</strong></p><p dir="RTL">تحدث مع الطبيب أو الممرضة قبل استخدام نكسيوم إذا:</p><p dir="RTL">&bull; كنت تعاني من مشكلات شديدة في الكبد.</p><p dir="RTL">&bull; كنت تعاني من مشكلات شديدة في الكُلى.</p><p dir="RTL">&bull; سبق أن عانيت من رد فعل جلدي بعد العلاج بدواء مشابه لنكسيوم يقلل من حمض المعدة.</p><p dir="RTL">&bull; كنت على وشك إجراء اختبار دم معين (كروموغرانين أ).</p><p>&nbsp;</p><p dir="RTL">يمكن أن يؤدّي نكسيوم إلى إخفاء أعراض ترتبط بأمراض أخرى. <strong>ولذلك، إذا حدث لك أي مما يلي قبل تناول نكسيوم أو بعد تناوله، فأخبر طبيبك على الفور: </strong></p><p dir="RTL">&bull; فقدان الكثير من وزنك دون أي سبب والمعاناة من مشكلات في البلع.</p><p dir="RTL">&bull; الشعور بألم في المعدة أو عسر هضم.</p><p dir="RTL">&bull; بدء تقيّؤ الطعام أو الدم.</p><p dir="RTL">&bull; إخراج براز أسود (براز به دم).</p><p>&nbsp;</p><p dir="RTL">قد يسبب مثبط ضخ بروتون مثل نكسيوم، خصوصًا عند تناوله لأكثر من عام واحد، خطرًا بسيطًا على الورك، أو المعصم، أو العمود الفقري حيث تصبح قابلة للكسر بشكل بسيط. أخبر الطبيب إذا كنت تعاني من تخلخل العظام أو إذا كنت تتناول كورتيكوستيرويد (الذي يزيد من خطر تخلخل العظام).</p><p dir="RTL">إذا أُصبتَ بطفح جلدي، خصيصًا في المناطق المعرضة للشمس، فأبلغ طبيبك بأسرع ما يمكن، حيث إنك قد تحتاج لوقف علاجك بنكسيوم. لا تنس أيضًا ذكر أي آثار مرضية أخرى مثل وجود ألم في مفاصلك.</p><p>&nbsp;</p><p dir="RTL"><strong>نكسيوم والأدوية الأخرى </strong></p><p dir="RTL">أخبر طبيبك أو الممرض إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى. ويشمل ذلك الأدوية التي تشتريها من دون وصفة طبية. ويعود ذلك إلى أنّ نكسيوم قد يؤثر على طريقة عمل بعض الأدوية، كما قد يكون لبعض الأدوية تأثير على نكسيوم.</p><p dir="RTL">يجب تجنب استخدام نكسيوم إذا كنت تتناول دواءً يحتوي على نيلفينافير (المستخدم في علاج عدوى الإيدز).</p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL">&bull; أتازانافير (المستخدم في علاج عدوى الإيدز).</p><p dir="RTL">&bull; كلوبيدوغريل (المستخدم في الوقاية من جلطات الدم).</p><p dir="RTL">&bull; كيتوكونازول أو إيتراكونازول أو فوريكونازول (المستخدمة في علاج حالات العدوى التي يتسبب فيها فطر معين).</p><p dir="RTL">&bull; إيرلوتينيب (المستخدم في علاج السرطان).</p><p dir="RTL">&bull; سيتالوبرام أو إيميبرامين أو كلوميبرامين (المستخدم في علاج الاكتئاب).</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull; الديازيبام (المستخدم في علاج القلق، أو إرخاء العضلات، أو علاج الصرع).</p><p dir="RTL">&bull; الفينيتوين (المستخدم في حالات الصرع). إذا كنت تتناول الفينيتوين ، فسيحتاج الطبيب لمراقبة حالتك عند بدء استخدام أو إيقاف نكسيوم.</p><p dir="RTL">&bull; الأدوية المستخدمة لترقيق الدم، مثل وارفارين. قد يحتاج الطبيب إلى مراقبة حالتك عند بدء استخدام أو إيقاف عقار نكسيوم.</p><p dir="RTL">&bull; سيلوستازول (المستخدم في علاج العرج المتقطع، وهو ألم في الساق عند السير ينتج عن عدم كفاية إمدادات الدم).</p><p dir="RTL">&bull; سيسابرايد (المستخدم في علاج عسر الهضم وحرقة الفؤاد).</p><p dir="RTL">&bull; ديجوكسين (المستخدم في علاج مشكلات القلب).</p><p dir="RTL">&bull; ميثوتريكيست (علاج كيميائي يستخدم بجرعات كبيرة في علاج السرطان) &ndash; إذا كنت تتناول جرعة كبيرة من ميثوتريكيست، فقد يوقف الطبيب علاج نكسيوم مؤقتًا.</p><p dir="RTL">&bull; تاكروليموس (في حالات زراعة الأعضاء).</p><p dir="RTL">&bull; الريفامبيسين (المستخدم في علاج السل).</p><p dir="RTL">&bull; عشبه سانت جون (<em>العرن المثقوب) </em>(المستخدمة في علاج الاكتئاب).</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل، والرضاعة، والخصوبة </strong></p><p dir="RTL">إذا كنتِ حاملاً أو تعتقدين أنكِ حامل أو تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلي قبل الخضوع للعلاج بهذا الدواء. سيقرر طبيبكِ إمكانية تناول نكسيوم خلال هذه الفترة.</p><p dir="RTL">ليس معروفًا ما إذا كان نكسيوم يمر عبر حليب الثدي أم لا. ومن ثم يجب تجنب استخدام نكسيوم أثناء الرضاعة الطبيعية.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">من غير المحتمل أن يؤثر نكسيوم على قدرتك على القيادة أو استخدام أي أدوات أو آلات. لكن في حالات غير شائعة، قد تحدث آثار جانبية مثل الدوار وضبابية الرؤية (انظر القسم 4). وعند الإصابة بهذه الأعراض، يجب تجنب القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عليك تناول نكسيوم دائمًا وفقًا لتوجيهات الطبيب. يتعيّن عليك مراجعة طبيبك أو الصيدلي إذا لم تكن متأكّدًا.</p><p>&nbsp;</p><p dir="RTL">يمكن إعطاء نكسيوم للأطفال والمراهقين في الفئة العمرية من عام واحد إلى 18 عامًا والبالغين وكبار السن.</p><p>&nbsp;</p><p dir="RTL"><strong>الخضوع للعلاج باستخدام نكسيوم </strong></p><p dir="RTL"><em>الاستخدام للبالغين </em></p><p dir="RTL">&bull; سيتولى طبيبك إعطاءك نكسيوم وسيقرر الكمية المطلوبة لك.</p><p dir="RTL">&bull; الجرعة الموصى بها هي 20 ملغ أو 40 ملغ مرة يوميًا.</p><p dir="RTL">&bull; إذا كنت تعاني من مشكلات شديدة في الكبد، فإن الجرعة القصوى هي 20&nbsp;ملغ مرة يوميًا (لعلاج GERD).</p><p dir="RTL">&bull; سيتم إعطاء الدواء لك عن طريق الحقن أو التسريب في أحد أوردتك. ويستغرق هذا ما يصل إلى 30 دقيقة.</p><p dir="RTL">&bull; الجرعة الموصى بها للوقاية من تكرار نزف قرحة المعدة أو قرحة الاثنى عشر هي 80 ملغ يتم أخذها بالتسريب الوريدي لمدة 30 دقيقة ثم التسريب المستمر بجرعة 8 ملغ/ساعة لمدة 3 أيام. إذا كنت تعاني من مشكلات شديدة في الكبد، فقد يكفي التسريب المستمر لجرعة 4 ملغ/ساعة لمدة 3 أيام.</p><p>&nbsp;</p><p dir="RTL"><em>الاستخدام في حالة الأطفال والمراهقين </em></p><p dir="RTL">&bull; سيتولى طبيبك إعطاءك نكسيوم وسيقرر الكمية المطلوبة لك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull; بالنسبة للأطفال في الفئة العمرية من عام واحد إلى 11 عامًا، الجرعة الموصى بها هي 10 أو 20 ملغ مرة يوميًا.</p><p dir="RTL">&bull; بالنسبة للأطفال في الفئة العمرية 12-18 عامًا، الجرعة الموصى بها هي 20 أو 40 ملغ مرة يوميًا.</p><p dir="RTL">&bull; يُعطى هذا الدواء عن طريق الحقن أو التسريب في الوريد. ويستغرق هذا ما يصل إلى 30 دقيقة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا حصلت على جرعة أكثر مما ينبغي من نكسيوم </strong></p><p dir="RTL">إذا اعتقدت أنك حصلت على جرعة أكثر مما ينبغي من نكسيوم، فتحدث إلى طبيبك على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأن جميع الأدوية، قد يتسبّب هذا الدواء في حدوث آثار جانبية على الرغم من أنها لا تصيب جميع المستخدمين.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا لاحظت أيًا من الآثار الجانبية الخطرة التالية، فتوقف عن تناول عقار نكسيوم واتصل بالطبيب على الفور: </strong></p><p>&nbsp;</p><p dir="RTL">&bull; حدوث نوبات مفاجئة من أزيز عند التنفس، أو تورم الشفتين واللسان والحلق أو الجسم، أو طفح جلدي، أو إغماء أو صعوبات في البلع (رد فعل ناتج عن حساسية حادة).</p><p dir="RTL">&bull; احمرار الجلد مع ظهور بثور أو تقشر. وقد يكون هناك أيضًا بثور حادة ونزيف في الشفتين، والعينين، والفم، والأنف، والأعضاء التناسلية. قد يكون هذا دليلاً على إصابتك بمرض &quot;متلازمة ستيفنز - جونسون&quot; أو &quot;تقشّر الأنسجة المتموّتة البَشْروية التسممي&quot;.</p><p dir="RTL">&bull; اصفرار الجلد، وتحول البول إلى اللون القاتم، وتعب، والتي قد تكون أعراضًا لمشاكل في الكبد.</p><p>&nbsp;</p><p dir="RTL">هذه الآثار نادرة، وقد تؤثر على شخص واحد من كل 1000 شخص.</p><p dir="RTL">تشمل الآثار الجانبية الأخرى ما يلي:</p><p dir="RTL"><strong>الشائعة </strong>(قد تؤثر على شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; آثار على المعدة أو الأمعاء: إسهال، أو ألم في المعدة، أو إمساك، أو ريح (انتفاخ البطن).</p><p dir="RTL">&bull; الشعور بغثيان أو التقيؤ.</p><p dir="RTL">&bull; رد فعل في موضع الحقن.</p><p dir="RTL">&bull; سلائل حميدة في المعدة.</p><p>&nbsp;</p><p dir="RTL"><strong>غير الشائعة </strong>(قد تؤثر على شخص واحد من كل 100 شخص)</p><p dir="RTL">&bull; تورم القدمين والكاحلين.</p><p dir="RTL">&bull; اضطراب النوم (الأرق).</p><p dir="RTL">&bull; دوار، أو شعور بالوخز مثل &quot;الدبابيس والإبر&quot;، أو شعور بالنعاس.</p><p dir="RTL">&bull; شعور بالدوار.</p><p dir="RTL">&bull; مشكلات في الإبصار مثل ضبابية الرؤية.</p><p dir="RTL">&bull; جفاف الفم.</p><p dir="RTL">&bull; تغيرات في اختبارات الدم التي تُجرى للتحقق من وظائف الكبد.</p><p dir="RTL">&bull; طفح جلدي، وطفح جلدي مائي (الشرى)، وحكة في الجلد.</p><p dir="RTL">&bull; حدوث حالات كسور في عظام الورك أو الرسغ أو العمود الفقري (عند استخدام جرعات عالية من نكسيوم ولفترة طويلة).</p><p>&nbsp;</p><p dir="RTL"><strong>النادرة </strong>(قد تؤثر على شخص واحد من كل 1000 شخص)</p><p dir="RTL">&bull; مشكلات في الدم مثل انخفاض عدد الخلايا البيضاء أو الصفائح الدموية. يمكن أن يتسبب ذلك في الضعف، أو الرضوض أو قد يزيد احتمالية الإصابة بعدوى.</p><p dir="RTL">&bull; انخفاض مستوى الصوديوم في الدم. يمكن أن يتسبب ذلك في الضعف والتقيؤ والتشنجات.</p><p dir="RTL">&bull; شعور بالهياج، أو الارتباك، أو الاكتئاب.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull; تغيرات في حاسة التذوق.</p><p dir="RTL">&bull; الشعور المفاجئ بعسر التنفس أو قصر التنفس (التشنج القصبي).</p><p dir="RTL">&bull; التهاب الفم من الداخل.</p><p dir="RTL">&bull; الإصابة بعدوى تُسمى &quot;السلاق&quot; وهي حمى قد تؤثّر على الأمعاء ويتسبب فيها فطر معين.</p><p dir="RTL">&bull; مشكلات في الكبد وتشمل اليرقان الذي قد يسبب اصفرار الجلد وإخراج بول داكن وشعورًا بالتعب.</p><p dir="RTL">&bull; تساقط الشعر (ثعلبة).</p><p dir="RTL">&bull; طفح جلدي عند التعرض لأشعة الشمس.</p><p dir="RTL">&bull; ألم المفاصل (ألم مفصلي) أو ألم العضلات (ألم عضلي).</p><p dir="RTL">&bull; الشعور بالاعتلال أو نقص الحيوية بشكل عام.</p><p dir="RTL">&bull; زيادة التعرّق.</p><p>&nbsp;</p><p dir="RTL"><strong>النادرة جدًا </strong>(قد تؤثر على شخص واحد من كل 10000 شخص)</p><p dir="RTL">&bull; تغيرات في عدد كرات الدم ويشمل ندرة المحببات (نقص كرات الدم البيضاء)</p><p dir="RTL">&bull; عدوانية.</p><p dir="RTL">&bull; رؤية أشياء غير موجودة أو الشعور بها أو سماعها (هلاوس).</p><p dir="RTL">&bull; مشكلات شديدة في الكبد تؤدي إلى فشل كبدي والتهاب في المخ.</p><p dir="RTL">&bull; ظهور مفاجئ لطفح جلدي شديد أو تبثر أو تقشر الجلد. قد يرتبط ذلك بحمى شديدة وألم في المفاصل (حمامي عديدة الأشكال، متلازمة ستيفنز - جونسون، تقشّر الأنسجة المتموّتة البشرويّة التسممي).</p><p dir="RTL">&bull; ضعف عضلي.</p><p dir="RTL">&bull; مشكلات شديدة في الكُلى.</p><p dir="RTL">&bull; تضخم الثديين لدى الرجال.</p><p>&nbsp;</p><p dir="RTL"><strong>غير المعروفة </strong>(لا يمكن تقدير معدل حدوثها من البيانات المتاحة)</p><p dir="RTL">&bull; إذا تناولت عقار نكسيوم لأكثر من ثلاثة أشهر، فقد تقل مستويات المغنيسيوم في دمك. ويمكن التعرف على نقص مستويات المغنيسيوم من خلال الشعور بالتعب، أو تقلصات عضلية لا إرادية، أو توهان، أو اختلاجات، أو دوار، أو زيادة سرعة ضربات القلب. إذا عانيت من أي من تلك الأعراض، فيرجى إخبار طبيبك على الفور. يمكن أن يؤدي نقص مستويات المغنيسيوم كذلك إلى نقص مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر الطبيب إجراء اختبارات منتظمة للدم لمراقبة مستويات المغنيسيوم.</p><p dir="RTL">&bull; التهاب الأمعاء (يؤدي إلى إسهال).</p><p dir="RTL">&bull; طفح جلدي، قد يصحبه ألم في المفاصل.</p><p>&nbsp;</p><p dir="RTL">في حالات نادرة جدًا، قد يؤثر نكسيوم على خلايا الدم البيضاء مما يؤدي إلى نقص المناعة. إذا كنت تعاني من عدوى مصحوبة بأعراض مثل الحمى مع تدهور <strong>حاد </strong>في الحالة العامة أو حمى مع أعراض عدوى موضعية، مثل ألم في الرقبة أو في الحلق أو الفم، أو صعوبات في التبول، فيجب استشارة الطبيب في أقرب وقت ممكن بحيث يمكن إجراء اختبار دم للتأكد من عدم وجود نقص في خلايا الدم البيضاء (ندرة المحببات). من المهم لك أن تقدم حينها معلومات عن دوائك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يتولى الطبيب وصيدلي المستشفى مسؤولية تخزين نكسيوم واستخدامه والتخلص منه بالطريقة الصحيحة.</p><p dir="RTL">&bull; لا تستخدم هذا العقار بعد تاريخ انتهاء صلاحيته المدون على العلبة وزجاجة الحقن. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المدوّن.</p><p dir="RTL">&bull; احتفظ بهذا الدواء بعيدًا عن متناول الأطفال وأنظارهم.</p><p dir="RTL">&bull; لا يُحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&bull; احفظ زجاجة الحقن في العلبة الكرتونية لحمايتها من الضوء. ومع هذا، يمكن تخزين زجاجات الحقن في الضوء الداخلي العادي خارج العلبة الكرتونية لمدة تصل إلى 24 ساعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما يحتويه نكسيوم </strong></p><p dir="RTL">المادة الفعالة هي إيزومبرازول صوديوم. وتحتوي كل زجاجة مسحوق محلول للحقن/التسريب على 42.5 ملغ من إيزومبرازول صوديوم، أي ما يعادل 40 ملغ من إيزومبرازول.</p><p dir="RTL">المكونات الأخرى هي ثاني إيديتات الصوديوم وهيدروكسيد الصوديوم. تحتوي كل زجاجة حقن على أقل من 1&nbsp;مللي مول من الصوديوم (23 ملغ) أي أنها تكاد تكون &quot;خالية من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">نكسيوم هو مسحوق أو قطع يتراوح لونه ما بين الأبيض والعاجي. ويتم تحويله إلى محلول قبل استخدامه.</p><p>&nbsp;</p><p dir="RTL">أحجام العبوات: 10 زجاجات حقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>AstraZeneca UK Limited</p><p>Luton,</p><p>United Kingdom</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NEXIUM 40 mg Powder for solution for injection/infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Each vial contains esomeprazole 40 mg (as sodium salt). Each vial contains <1 mmol sodium
For a full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection/infusion

White to off-white porous cake or powder

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nexium for injection and infusion is indicated for</p><p>&bull;&nbsp;&nbsp;&nbsp; gastric antisecretory treatment when the oral route is not possible, such as:</p><p>&minus;&nbsp;&nbsp;&nbsp; gastroesophageal reflux disease (GERD) in patients with esophagitis and/or severe symptoms of reflux.</p><p>&minus;&nbsp;&nbsp;&nbsp; healing of gastric ulcers associate with NSAID therapy.</p><p>&minus;&nbsp;&nbsp;&nbsp; prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.</p><p>Nexium IV for injection and infusion is indicated in children and adolescents aged</p><p>1‐18 years for:</p><p>&bull;&nbsp;&nbsp;&nbsp; Gastric antisecretory treatment when the oral route is not possible, such as gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>P</u><u>osology</u></p><p><em>Gastric antisecretory treatment when the oral route is not possible</em></p><p>Patients who cannot take oral medication may be treated parenterally with 20-40 mg once daily. Patients with reflux oesophagitis should be treated with 40 mg once daily. Patients treated symptomatically for reflux disease should be treated with 20 mg once daily.</p><p>For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily. For prevention of gastric and duodenal ulcers associated with NSAID therapy, patients at risk should be treated with 20 mg once daily.</p><p>Usually the intravenous treatment duration is short and transfer to oral treatment should be made as soon as possible.</p><p>&nbsp;</p><p><em>Prevention of rebleeding of gastric and duodenal ulcers</em></p><p>Following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be administered as a bolus infusion over 30 minutes, followed by a continuous intravenous infusion of 8 mg/h given over 3 days (72 hours).</p><p>The parenteral treatment period should be followed by oral acid suppression therapy. <u>Methodofadministration</u></p><p>For preparation of reconstituted solution, see section 6.6.</p><p>&nbsp;</p><p>Injection</p><p><u>40 mg dose</u></p><p>5 ml of the reconstituted solution (8 mg/ml) should be given as an intravenous injection over a period of at least 3 minutes.</p><p>&nbsp;</p><p><u>20 mg dose</u></p><p>2.5 ml or half of the reconstituted solution (8 mg/ml) should be given as an intravenous injection over a period of at least 3 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p>Infusion</p><p><u>40 mg dose</u></p><p>The reconstituted solution should be given as an intravenous infusion over a period of 10 to</p><p>30 minutes.</p><p>&nbsp;</p><p><u>20 mg dose</u></p><p>Half of the reconstituted solution should be given as an intravenous infusion over a period of</p><p>10 to 30 minutes. Any unused solution should be discarded.</p><p>&nbsp;</p><p><u>80 mg bolus dose</u></p><p>The reconstituted solution should be given as a continuous intravenous infusion over 30 minutes.</p><p>&nbsp;</p><p><u>8 mg/h dose</u></p><p>The reconstituted solution should be given as a continuous intravenous infusion over a period of 71.5 hours (calculated rate of infusion of 8 mg/h. See section 6.3 for shelf-life of the reconstituted solution.).</p><p>&nbsp;</p><p>Children and adolescents:</p><p>Nexium IV for injection and infusion is indicated in children and adolescents aged 1‐18 years for:</p><p>&bull; Gastric antisecretory treatment when the oral route is not possible, such as gastroesophageal reflux disease (GERD) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.</p><p>&nbsp;</p><p><em>I</em><em>mpaired renal function</em></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution. (See section 5.2).</p><p>&nbsp;</p><p><em>I</em><em>mpaired hepatic function</em></p><p>GERD: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum daily dose of 20 mg Nexium should not be exceeded. (See section 5.2).</p><p>&nbsp;</p><p>Bleeding ulcers: Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, following an initial bolus dose of</p><p>80 mg Nexium for infusion, a continuous intravenous infusion dose of 4 mg/h for 71.5 hours may be sufficient (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Dose adjustment is not required in the elderly.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance esomeprazole or to other substituted benzimidazoles or to any of the excipients of this medicinal product.

Esomeprazole should not be used concomitantly with nelfinavir (See section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cutaneous and Systemic Lupus Erythematosus</p><p>Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have</p><p>been reported in patients taking PPls, including esomeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority ofPPI-induced lupus erythematosus cases were CLE.</p><p>&nbsp;</p><p>The most common form of CLE reported in patients treated with PPls was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement.</p><p>&nbsp;</p><p>&nbsp;</p><p>Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPls. &nbsp;PPI associated SLE is usually milder than non-drug induced &nbsp;SLE. Onset of &nbsp;SLE &nbsp;typically &nbsp;occurred &nbsp;within &nbsp;days &nbsp;to &nbsp;years &nbsp;after &nbsp;initiating &nbsp;treatment primarily &nbsp;in &nbsp;patients &nbsp;ranging &nbsp;from &nbsp;young &nbsp;adults &nbsp;to &nbsp;the &nbsp;elderly. &nbsp;The &nbsp;majority &nbsp;of patients presented with rash; however, arthralgia and cytopenia were also reported.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Avoid &nbsp;administration&nbsp; &nbsp;of &nbsp;PPis &nbsp;for &nbsp;longer &nbsp;than &nbsp;medically &nbsp;indicated. &nbsp;If &nbsp;signs &nbsp;or symptoms consistent with CLE or SLE are noted in patients receiving esomeprazole, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most &nbsp;patients &nbsp;improve &nbsp;with &nbsp;discontinuation &nbsp;of &nbsp;the &nbsp;PPI &nbsp;alone &nbsp;in &nbsp;4 &nbsp;to &nbsp;12 &nbsp;weeks. Serological &nbsp;testing &nbsp;such &nbsp;as antinuclear &nbsp;antibody &nbsp;(ANA) &nbsp;test &nbsp;may &nbsp;be positive &nbsp;and elevated &nbsp;serological&nbsp; &nbsp;test&nbsp; &nbsp;results &nbsp;may take &nbsp;longer to &nbsp;resolve&nbsp; &nbsp;than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinical manifestations.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider&nbsp; &nbsp;stopping&nbsp; &nbsp;Esomeprazole&nbsp; &nbsp;Gastro-resistant&nbsp; &nbsp;Tablets.&nbsp; &nbsp;SCLE &nbsp;after&nbsp; &nbsp;previous treatment with a proton pump inhibitor may increase the risk of SCLE &nbsp;with other proton pump inhibitors.</p><p>&nbsp;</p><p>Acute Interstitial Nephritis</p><p>Acute interstitial nephritis has been observed in patients taking PPis including esomeprazole. Acute interstitial &nbsp;nephritis may occur at any point during PPI therapy</p><p>and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue esomeprazole if acute interstitial nephritis develops.</p><p><em>Clostridium </em>difficile-Associated Diarrhea</p><p>Published observational studies suggest that PPI therapy like esomeprazole &nbsp;may be associated&nbsp; &nbsp;with&nbsp; &nbsp;an&nbsp; &nbsp;increased&nbsp; &nbsp;risk&nbsp; &nbsp;of&nbsp; &nbsp;<em>Clostridium&nbsp; &nbsp;</em>dijjicile-associated&nbsp;&nbsp; &nbsp;diarrhea, especially &nbsp;in hospitalized &nbsp;patients. This diagnosis should &nbsp;be considered &nbsp;for diarrhea that does not improve (see section 4.8).</p><p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p><p>&nbsp;</p><p>&nbsp;</p><p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with Nexium may alleviate symptoms and delay diagnosis.</p><p>&nbsp;</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>(see section 5.1).</p><p>&nbsp;</p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded.</p><p>&nbsp;</p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p>&nbsp;</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>&nbsp;</p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like esomeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness</p><p>and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase</p><p>may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p>&nbsp;</p><p><em>I</em><em>nterference with laboratory tests</em></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, esomeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>Medicinal products with &nbsp;pH dependent absorption</p><p>Co-administration&nbsp; &nbsp;of &nbsp;omeprazole&nbsp; &nbsp;in &nbsp;healthy &nbsp;subjects&nbsp; &nbsp;and &nbsp;in &nbsp;transplant&nbsp; &nbsp;patients receiving mycophenolate &nbsp;mofetil (MMF) has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric PH.</p><p>The &nbsp;clinical &nbsp;relevance &nbsp;of &nbsp;reduced &nbsp;MPA exposure &nbsp;on&nbsp; organ &nbsp;rejection &nbsp;has&nbsp; not &nbsp;been established &nbsp;in&nbsp; transplant &nbsp;patients &nbsp;receiving &nbsp;esomeprazole &nbsp;and &nbsp;MMF. &nbsp;Use esomeprazole &nbsp;with caution in transplant patients receiving MMF.</p><p>&nbsp;</p><p><strong>E</strong><strong>f</strong><strong>f</strong><strong>ect</strong><strong>s of esomeprazole on the pharmacokinetics of other drugs:</strong></p><p><em>Me</em><em>dicinal products with pH dependent absorption</em></p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease</p><p>or increase the absorption of&nbsp; medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should then be reinforced.</p><p>&nbsp;</p><p>Omeprazole has been reported to interact with some protease inhibitors. &nbsp;The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP 2C19.&nbsp; For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of</p><p>omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, Cmax and Cmin). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg qd) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg qd without omeprazole 20 mg qd. Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, Cmax and Cmin by 36&ndash;39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%.</p><p>&nbsp;</p><p>&nbsp;</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg qd). &nbsp;Treatment with omeprazole</p><p>20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). Treatment with esomeprazole 20 mg qd had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg qd had no effect on the exposure of lopinavir (with concomitant ritonavir). Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended and concomitant administration with esomeprazole and nelfinavir is contraindicated.</p><p>&nbsp;</p><p><em>Drugs metabolised by CYP2C19</em></p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme. Thus, when esomeprazole is combined with drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. Concomitant oral administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam. Concomitant oral administration of 40 mg esomeprazole and phenytoin resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn. Omeprazole (40 mg once daily)</p><p>increased voriconazole (a CYP2C19 substrate) Cmax and AUC&tau; by 15% and 41%, respectively.</p><p>&nbsp;</p><p>Concomitant oral administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post- marketing of oral esomeprazole, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.</p><p>&nbsp;</p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp; In healthy volunteers, concomitant oral administration of 40 mg esomeprazole and cisapride&nbsp;&nbsp;&nbsp; resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a</p><p>31% prolongation of elimination half-life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole.</p><p>&nbsp;</p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p>&nbsp;</p><p>No <em>in vivo </em>interaction studies have been performed with the high dose intravenous regimen (80mg+8mg/h). The effect of esomeprazole on drugs metabolised by CYP2C19 may be more pronounced during this regimen, and patients should be monitored closely for adverse effects, during the 3-day intravenous treatment period.</p><p>&nbsp;</p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/ pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o.daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40% and resulting in decreased maximum inhibition of (ADP induced) platelet aggression by an average of 14%.</p><p>&nbsp;</p><p>&nbsp;</p><p>When clopidogrel was gi ven together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study i n healthy subjects there was a</p><p>decreased exposure by almost 40% of the active metabolite of clopidogrel . However, the maximum levels of inhibition of (ADP induced) platel et aggregation in these subj ects were the same in the</p><p>clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups.</p><p>&nbsp;</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged.</p><p>&nbsp;</p><p><em>Unknown mechanism</em></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus.</p><p>&nbsp;</p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p>&nbsp;</p><p><em>Effects of other drugs on the pharmacokinetics of esomeprazole</em></p><p>Esomeprazole is metabolised by CYP2C19 and CYP3A4. Concomitant oral administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP 3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUC&tau; &nbsp;by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p>&nbsp;</p><p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&rsquo;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For esomeprazole limited data on exposed pregnancies are available. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/fetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing Nexium to pregnant women.</p><p>&nbsp;</p><p>It is not known whether esomeprazole is excreted in human breast milk. No studies in lactating women have been performed. Therefore Nexium should not be used during breast- feeding.</p><p>&nbsp;</p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not</p><p>indicate effects with respect to fertility</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) has been reported (see section 4.8). If affected patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>T</strong><strong>o report any side effect(s):</strong></p><p><strong>S</strong><strong>audi Arabia:</strong></p><p>-&nbsp;&nbsp;&nbsp; National Pharmacovigilance Center (NPC):</p><p>o&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp; Call NPC at :</p><p>+966-11-2038222 Exts: 2317-2356-2353-2354-2334-2340</p><p>o&nbsp; Toll free: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><strong>Other GCC states:</strong></p><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Summary of the safety profile</strong></p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post‐marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose‐related adverse reactions have been identified.</p><p>&nbsp;</p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole administered orally or intravenously and post-marketing when administered orally. The reactions are classified according to frequency; very common &ge;1/10; common &ge;1/100 to &lt;1/10; uncommon &ge;1/1,000 to &lt;1/100; rare &ge;1/10,000 to &lt;1/1,000; very rare &lt;1/10,000; not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>B</strong><strong>lood and lymphatic system disorders: </strong>Rare: Leukopenia, thrombocytopenia Very rare: Agranulocytosis, pancytopenia</p><p>&nbsp;</p><p><strong>Immune system disorders:</strong></p><p>Rare: Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p><p>&nbsp;</p><p><strong>Met</strong><strong>abolism and nutrition disorders:</strong></p><p>Uncommon: Peripheral oedema</p><p>Rare: Hyponatraemia</p><p>&nbsp; Not known: Hypomagnesaemia may also be associated with hypokalemia, severe hypomagnesaemia can correlate with hypocalcaemia</p><p>&nbsp;</p><p><strong>P</strong><strong>sychiatric disorders:</strong></p><p>Uncommon: Insomnia</p><p>Rare: Agitation, confusion, depression</p><p>Very rare: Aggression, hallucinations</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Nervous system disorders:</strong></p><p>Common: Headache</p><p>Uncommon: Dizziness, paraesthesia, somnolence</p><p>Rare: Taste disturbance</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>E</strong><strong>ye disorders:</strong></p><p>Uncommon: Blurred vision</p><p>&nbsp;</p><p><strong>E</strong><strong>ar and labyrinth disorders:</strong></p><p>Uncommon: Vertigo</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders:</strong></p><p>Rare: Bronchospasm</p><p>&nbsp;</p><p><strong>G</strong><strong>astrointestinal disorders:</strong></p><p>Common: Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, Fundic gland polyps (benign)</p><p>Uncommon: Dry mouth</p><p>Rare: Stomatitis, gastrointestinal candidiasis</p><p>Not known: Microscopic colitis</p><p>&nbsp;&nbsp;</p><p>&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders:</strong></p><p>Uncommon: Increased liver enzymes</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare: Hepatitis with or without jaundice</p><p>Very rare: Hepatic failure, encephalopathy in patients with pre-existing liver disease</p><p>&nbsp;</p><p><strong>Sk</strong><strong>in and subcutaneous tissue disorders: </strong>Common: Administration site reactions* Uncommon: Dermatitis, pruritus, rash, urticaria Rare: Alopecia, photosensitivity</p><p>Very rare: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis</p><p>(TEN)</p><p>&nbsp;Not known: Subacute cutaneous lupus &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;erythematosus.</p><p>&nbsp;</p><p><strong>M</strong><strong>u</strong><strong>sculoskeletal and connective tissue disorders: </strong>Uncommon: Fracture of the hip, wrist or spine (see section 4.4) Rare: Arthralgia, myalgia</p><p>Very rare: Muscular weakness</p><p>&nbsp;</p><p><strong>Renal and urinary disorders:</strong></p><p>Very rare: Interstitial nephritis; in some patients renal failure has been reported concomitantly.</p><p>&nbsp;</p><p><strong>Reproductive system and breast disorders:</strong></p><p>Very rare: Gynaecomastia</p><p>&nbsp;</p><p><strong>G</strong><strong>e</strong><strong>n</strong><strong>er</strong><strong>al disorders and administration site conditions:</strong></p><p>Rare: Malaise, increased sweating</p><p>*Administration site reactions have mainly been observed in a study with high-dose exposure over 3 days (72 hours). See section 5.3.</p><p>Irreversible visual impairment has been reported in isolated cases of critically ill patients who have received omeprazole (the racemate) intravenous injection, especially at high doses, but no causal relationship has been established.</p><p>&nbsp;</p><p>Post marketing expeience:</p><p>The following adverse reactions have been identified during post-approval &nbsp;use of esomeprazole. Because these reactions are reported voluntarily from a population of uncertain &nbsp;size, &nbsp;it &nbsp;is &nbsp;not &nbsp;always &nbsp;possible &nbsp;to &nbsp;reliably &nbsp;estimate&nbsp; &nbsp;their &nbsp;frequency&nbsp;&nbsp; or establish a causal relationship to drug exposure.</p><p><u>Gastrointestinal disorders</u>: pancreatitis</p><p><u>Immune system disorders</u>: systemic lupus erythematosus</p><p><u>Infections and Infestations</u> disorders: Clostridium difficile-associated diarrhea</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with an oral dose of 280 mg were gastrointestinal symptoms and weakness. Single oral doses of 80 mg esomeprazole and intravenous doses of 308 mg esomeprazole over 24 hours were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitor</p><p>ATC Code: A02B C05</p><p>&nbsp;</p><p>Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity.</p><p>&nbsp;</p><p><em>Site and mechanism of action</em></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+-ATPase &ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p>&nbsp;</p><p><em>Effect on gastric acid secretion</em></p><p>After 5 days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above</p><p>4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD patients. The effect is similar irrespective of whether esomeprazole</p><p>is administered orally or intravenously.</p><p>&nbsp;</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown after oral administration of esomeprazole.</p><p>&nbsp;</p><p>During intravenous administration of 80 mg esomeprazole as a bolus infusion over 30 minutes followed by a continuous intravenous infusion of 8 mg/h for 23.5 hours, intragastric pH above 4, and pH above 6 was maintained for a mean time of 21 hours, and 11-13 hours, respectively, over 24 hours in healthy subjects.</p><p>&nbsp;</p><p><em>T</em><em>herapeutic effects of acid inhibition</em></p><p>Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78%</p><p>of patients after 4 weeks, and in 93% after 8 weeks of oral treatment.</p><p>&nbsp;</p><p>In a randomized, double blind, placebo-controlled clinical study, patients with endoscopically confirmed peptic ulcer bleeding characterised as Forrest Ia, Ib, IIa or IIb (9%, 43%, 38% and</p><p>10 % respectively) were randomized to receive Nexium solution for infusion (n=375) or placebo (n=389). &nbsp;Following endoscopic haemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours.&nbsp; After the initial 72 hour period, all patients received open-label 40 mg oral Nexium for 27 days for acid suppression.&nbsp; The</p><p>occurrence of rebleeding within 3 days was 5.9% in the Nexium treated group compared to</p><p>10.3% for the placebo group. At 30 days post-treatment, the occurrence of rebleeding in the</p><p>Nexium treated versus the placebo treated group was 7.7% vs 13.6%.</p><p>&nbsp;</p><p><em>Other effects related to acid inhibition</em></p><p>During treatment with antisecretory medicinal productsserum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Literature reports indicate that proton pump inhibitor treatment should be stopped at least 5 days before</p><p>CgA measurement. If CgA and gastrine levels have not normalised after 5 days, measurements should be repeated 14 days after cessation of esomeprazole treatment.</p><p>&nbsp;</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed during long term treatment with esomeprazole. The findings are considered to be of no clinical significance.</p><p>&nbsp;</p><p>During long-term oral treatment with antisecretory drugs gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>&nbsp;</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>and, in hospitalised patients, possibly also <em>Clostridium difficile</em>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Distribution</em></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately</p><p>0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p>&nbsp;</p><p><em>Me</em><em>tabolism and excretion</em></p><p>Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19,</p><p>&nbsp;</p><p>responsible&nbsp;&nbsp; for&nbsp;&nbsp; the&nbsp; &nbsp;formation&nbsp; &nbsp;of&nbsp;&nbsp; the&nbsp;&nbsp; hydroxy-&nbsp; &nbsp;and&nbsp; &nbsp;desmethyl&nbsp; &nbsp;metabolites&nbsp;&nbsp; of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p>&nbsp;</p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional</p><p>CYP2C19 enzyme, extensive metabolisers.</p><p>&nbsp;</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once- daily dosing. Total exposure (AUC) increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p>&nbsp;</p><p>Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration.</p><p>&nbsp;</p><p>Following repeated doses of 40 mg administered as intravenous injections, the mean peak plasma concentration is approx. 13.6 micromol/l. The mean peak plasma concentration after corresponding oral doses is approx. 4.6 micromol/l. A smaller increase (of approx</p><p>30%) can be seen in total exposure after intravenous administration compared to oral administration. There is a dose-linear increase in total exposure following intravenous administration of esomeprazole as a 30-minute infusion (40 mg, 80 mg or 120 mg) followed by a continuous infusion (4 mg/h or 8 mg/h) over 23.5 hours.</p><p>&nbsp;</p><p>The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost</p><p>80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.</p><p>&nbsp;</p><p><em>Special patient populations</em></p><p>Approximately 2.9&plusmn;1.5% of the population lacks a functional CYP2C19 enzyme and is called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg oral esomeprazole, the mean total exposure was approximately 100% higher in poor metabolisers than in subjects with a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. Similar differences have been seen for intravenous administration of esomeprazole. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71-80 years of age).</p><p>&nbsp;</p><p>Following a single oral dose of 40 mg esomeprazole the mean total exposure is approximately 30% higher in females than in males. No gender difference is seen after repeated once-daily administration. Similar differences have been observed for intravenous administration of esomeprazole. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the total exposure of esomeprazole. Therefore, a maximum dose of 20 mg should not be exceeded in GERD patients with severe dysfunction. For patients with bleeding ulcers and severe liver impairment, following an initial bolus dose of 80 mg, a maximum continuous intravenous infusion dose of 4 mg/h for 71.5 hours may be sufficient. Esomeprazole or its major metabolites do not show any tendency to accumulate with once- daily dosing.</p><p>&nbsp;</p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical studies reveal no particular hazard for humans, based on conventional studies of single and repeated dose toxicity, embryo-foetal toxicity and mutagenicity. Oral carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid, and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion. In the non-clinical program for esomeprazole intravenous formulation there was no evidence of vaso-irritation but a slight tissue inflammatory reaction at the injection site after subcutaneous (paravenous) injection was noted.&nbsp; See section 4.8.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Disodium edetate</p><p>Sodium hydroxide (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should not be used with other medicinal products except those mentioned in 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years in all climate zone.

Shelf-life after reconstitution
Chemical and physical in-use stability has been demonstrated for 12 hours at 30°C. From a microbiological point of view, the product should be used immediately.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package, in order to protect from light. Vials can however be stored exposed to normal indoor light outside the box for up to 24 hours. Do not store above</p><p>30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml vial made of colourless borosilicate glass, type I<strong><em>. </em></strong>Stopper made of bromobutyl latex- free rubber, cap made of aluminium and a plastic flip-off seal.</p><p>&nbsp;</p><p>Pack sizes: 10 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The reconstituted solution should be inspected visually for particulate matter and discoloration prior to administration. Only clear solution should be used. For single use only.</p><p>If the entire reconstituted content of the vial is not required, any unused solution should be discarded in accordance with local requirements.</p><p>&nbsp;</p><p><u>I</u><u>njection 40 mg</u></p><p>A solution for injection (8 mg/ml) is prepared by adding 5 ml of 0.9% sodium chloride for intravenous use to the esomeprazole 40 mg vial.</p><p>The reconstituted solution for injection is clear and colourless to very slightly yellow. <u>Infusion 40 mg</u></p><p>A solution for infusion is prepared by dissolving the content of one vial with esomeprazole</p><p>40 mg in up to 100 ml of 0.9% sodium chloride for intravenous use.</p><p>&nbsp;</p><p><u>I</u><u>n</u><u>f</u><u>usion 80 mg</u></p><p>A solution for infusion is prepared by dissolving the contents of two vials of esomeprazole</p><p>40 mg in up to 100 ml of 0.9% sodium chloride for intravenous use.</p><p>&nbsp;</p><p>The reconstituted solution for infusion is clear and colourless to very slightly yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca UK
Luton,
United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>